Maravai LifeSciences Holdings, Inc.

NasdaqGS:MRVI 주식 보고서

시가총액: US$1.7b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Maravai LifeSciences Holdings 대차 대조표 상태

재무 상태 기준 확인 4/6

Maravai LifeSciences Holdings 의 총 주주 지분은 $777.4M 이고 총 부채는 $523.3M, 이는 부채 대 자기자본 비율을 67.3% 로 가져옵니다. 총자산과 총부채는 각각 $1.4B 및 $667.3M 입니다.

주요 정보

67.3%

부채 비율

US$523.33m

부채

이자 보상 비율n/a
현금US$561.69m
주식US$777.39m
총 부채US$667.25m
총 자산US$1.44b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Jun 12

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19
Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14
Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Maravai Faces Skeptical Investors As Pandemic Enters New Period

Jan 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Dec 02
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Oct 07
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

재무 상태 분석

단기부채: MRVI 의 단기 자산 ( $667.9M )이 단기 부채( $59.0M ).

장기 부채: MRVI 의 단기 자산( $667.9M )이 장기 부채( $608.2M ).


부채 대 자본 내역 및 분석

부채 수준: MRVI 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: MRVI 의 부채 대 자기자본 비율은 지난 5년간 229.6% 에서 67.3% 로 감소했습니다.

부채 범위: MRVI 의 부채는 영업 현금 흐름 ( 6.2% )에 의해 잘 갚지 않음입니다.

이자 보장: MRVI 의 부채에 대한 이자 지급EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.


대차 대조표


건강한 기업 발견하기